Peptides DB
Research-centric peptide and protocol reference hub
Study 40 of 46Orforglipron (LY-3502970) literatureObesity pillars · RCT · Phase 3High-impact journal2026

Orforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials.

Orforglipron treatment was associated with improvements in physical and psychosocial functioning in adults with obesity, particularly in those with higher baseline BMI and physical limitations.

Read at Obesity pillarsAdd to compare

Where it sits

this study against the rest of the orforglipron (ly-3502970) corpus
14
Preclinical
9
Observational
1
Open-label
14
Randomised · this one
8
Reviews

Summary and findings

This study evaluated the effects of orforglipron on physical and psychosocial functioning in adults with obesity over 72 weeks. The analysis included patient-reported outcomes from the ATTAIN phase 3 trials. Improvements were noted in health-related quality of life and physical function compared to placebo.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.Phase 32026

Abstract

The authors’ words, as Obesity pillars supplied them

<h4>Background</h4>In ATTAIN, phase 3, randomized, placebo-controlled trials, orforglipron treatment resulted in substantial weight reduction among people with obesity with or without type 2 diabetes.<h4>Methods</h4>This was a prespecified secondary and post-hoc analyses of patient-reported outcomes (PRO) (ATTAIN-1 and ATTAIN-2). Health-Related Quality of Life (HRQoL) was assessed from baseline to week 72 (efficacy estimand) using Short Form-36 Version 2 Health Survey acute form (SF-36v2), Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT), EQ-5D-5L and associated EQ visual analog scale (EQ VAS), and Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) for Physical Activity. Post-hoc analysis assessed changes in outcomes among orforglipron-treated participants by body mass index (BMI) subgroups (<35 kg/m<sup>2</sup>, ≥35 to <40 kg/m<sup>2</sup>, and ≥40 kg/m<sup>2</sup>) and by baseline physical function limitations, as defined by PGIS. A mixed-model for repeated-measures (MMRM) was used, adjusting for treatment and key covariates.<h4>Results</h4>Across both ATTAIN trials, participants receiving orforglipron demonstrated greater improvements than those on placebo in PROs across most SF-36v2, IWQOL-Lite-CT and EQ-5D-5L domain scores from baseline through week 72. Significant improvements were observed across PROs related to physical function. In the exploratory subgroup analyses, participants in ATTAIN-1 with higher baseline BMI and those with baseline physical function limitations were more likely to have greater improvements.<h4>Conclusion</h4>Across the ATTAIN-1 and ATTAIN-2 trials, orforglipron treatment was associated with substantial body weight reduction and improvements in patient-reported HRQoL, with consistent enhancements in physical functioning and heterogeneous effects on psychosocial functioning.<b>ATTAIN-1: NCT05869903; ATTAIN-2:</b>NCT05872620.

Background

This paper addresses the impact of orforglipron on physical and psychosocial functioning in adults with obesity, a population that often experiences impaired quality of life. Prior studies have indicated that weight reduction can lead to improvements in health-related quality of life, but specific outcomes related to orforglipron had not been thoroughly evaluated. This study is significant as it explores patient-reported outcomes in the context of a phase 3 trial.

Methods

The study involved prespecified secondary and post-hoc analyses from the ATTAIN-1 and ATTAIN-2 trials, which were phase 3, randomized, placebo-controlled trials. The population included adults with obesity, and the outcomes were assessed using various validated questionnaires over a duration of 72 weeks. The primary focus was on health-related quality of life and physical functioning as measured by multiple PRO instruments.

Results

Participants receiving orforglipron demonstrated greater improvements in PROs compared to placebo, particularly in physical function. However, specific numeric findings, including effect sizes and p-values, were not reported in the abstract. The exploratory subgroup analyses suggested that individuals with higher baseline BMI and those with physical function limitations experienced more significant improvements.

Interpretation

The findings suggest that orforglipron may positively influence health-related quality of life and physical functioning in individuals with obesity, aligning with previous literature on weight loss and quality of life. However, the lack of detailed numeric outcomes limits the ability to assess the clinical significance of these improvements. Additionally, the reliance on post-hoc analyses raises concerns about the robustness of the conclusions.

Key findings

  • Not reported in abstract.

Limitations

  • Not reported in abstract.
  • Post-hoc analyses may limit the robustness of the findings.
  • Sample sizes for specific outcomes were not provided.
  • No specific numeric outcomes or effect sizes reported.

Elsewhere in the Orforglipron (LY-3502970) corpus

ASafety and efficacy of oral non-peptide GLP-1 receptor agonist in non- diabetic obese patients; systematic review and meta-analysis of randomized controlled trialsbiorxiv-preprint · 2026 · MD −7.61% body weight reduction vs placebo, 95% CI −8.59 to −6.62; p<0.0001; I²=74.0%reviewAOrforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA).JAMA · 2026 · Mean AHI change was -17.8 for orforglipron vs -4.5 for placebo in trial 1, difference -13.2 [95% CI, -17.7 to -8.7]; P < 0.001 at 52 weeks.HumanDOrforglipron for Obstructive Sleep Apnea: Research Summary.JAMA · 2026reviewAEfficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m(2) and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial.Obesity pillars · 2026 · At Week 72, orforglipron 17.2 mg was associated with a mean percent body weight reduction of -13.5% versus placebo at -0.3%, nominal p < 0.001.HumanAOrforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials.Obesity pillars · 2026 · Not reported in abstract.HumanBPreferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete-Choice Experiment (OPTIC).Diabetes, obesity & metabolism · 2025 · n=800 · 84.2% preferred Treatment A vs 15.8% for Treatment B.Human